Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H26N2O5 |
| Molecular Weight | 398.4522 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC1=CC=C(C=C1)C2=CC3=CN([C@H]4C[C@H](O)[C@@H](CO)O4)C(=O)N=C3O2
InChI
InChIKey=MFGSDSRTGUVZQG-DFQSSKMNSA-N
InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
| Molecular Formula | C22H26N2O5 |
| Molecular Weight | 398.4522 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Valnivudine, also known as FV-100, a prodrug that has been indicated as a potential antiviral for the treatment of shingles (herpes zoster) that could both reduce the pain burden of the acute episode and reduce the incidence of post‐herpetic neuralgia compared to available treatments. Phase I clinical trial with FV100 showed safety and tolerability in healthy volunteers. Valnivudine also participated in phase III, where its efficacy was compared with valacyclovir; however, the study was terminated.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. | 2017-07 |
|
| Herpes simplex virus and varicella zoster virus: recent advances in therapy. | 2015-12 |
|
| FV-100: the most potent and selective anti-varicella zoster virus agent reported to date. | 2010-01-05 |
|
| Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase. | 2004-03-19 |
|
| Synthesis and antiviral evaluation of some 3'-fluoro bicyclic nucleoside analogues. | 2004 |
|
| Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. | 2003-05 |
|
| Bicyclic nucleoside inhibitors of varicella-zoster virus: effect of terminal aryl substitution in the side-chain. | 2002-09 |
|
| Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. | 2002-07-18 |
|
| Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. | 2002-05 |
|
| Alkyloxyphenyl furano pyrimidines as potent and selective anti-VZV agents with enhanced water solubility. | 2002-03 |
|
| Novel aryl substituted bicyclic furo nucleosides as extremely potent and selective anti-VZV agents. | 2001-09-21 |
|
| Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. | 2000-12-28 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:22:47 GMT 2025
by
admin
on
Mon Mar 31 21:22:47 GMT 2025
|
| Record UNII |
5XGI48Q2DH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
319425-66-6
Created by
admin on Mon Mar 31 21:22:47 GMT 2025 , Edited by admin on Mon Mar 31 21:22:47 GMT 2025
|
PRIMARY | |||
|
493485
Created by
admin on Mon Mar 31 21:22:47 GMT 2025 , Edited by admin on Mon Mar 31 21:22:47 GMT 2025
|
PRIMARY | |||
|
5XGI48Q2DH
Created by
admin on Mon Mar 31 21:22:47 GMT 2025 , Edited by admin on Mon Mar 31 21:22:47 GMT 2025
|
PRIMARY | |||
|
DTXSID60185781
Created by
admin on Mon Mar 31 21:22:47 GMT 2025 , Edited by admin on Mon Mar 31 21:22:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
